The effect of multiple sclerosis B-cell therapy on vaccination Seraj aldeen hussien altarhun

Abstract

Multiple sclerosis (MS) is a disease that affects the brain and spinal cord, resulting in a variety of symptoms such as vision, arm or leg movement, sensation, and balance disorders. Depletion of CD20+ B cells has been shown to be a highly effective method of suppressing inflammatory activity in MS patients. Anti-CD20 monoclonal antibodies (mAbs) such as rituximab, ocrelizumab, and ofatumumab have been developed for MS treatment. CD20 is a cell-surface molecule expressed on most B cell subsets, including pre-B cells, immature, mature, and memory B cells. CD20 is not, however, expressed on pro-B cells, or on plasmablasts and plasma cells. patients treated with rituximab and ocrelizumab do not develop rebound inflammation following B-cell reconstitution Vaccination is an easy, safe, and efficient technique to protect people from dangerous diseases before they become infected.